We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DexCom to Roll Out Reimagined Stelo App With Global Expansion Plans
Read MoreHide Full Article
Key Takeaways
DexCom will roll out its redesigned Stelo app in the United States starting in July.
Stelo is expected to launch in four international markets later this year, with more expansion to 2027.
DexCom gained FDA clearance for Stelo use in children aged 2 and older who are not using insulin.
DexCom (DXCM - Free Report) recently announced that it will begin rolling out its fully reimagined Stelo app experience in the United States starting in July. The updated app, available for Apple iPhone and Android users, is designed to make glucose insights more accessible and actionable for individuals seeking to better understand their metabolic health.
Alongside the app launch, DexCom reiterated its plans to expand Stelo internationally. The platform is expected to launch in the United Kingdom, Australia, New Zealand and South Korea later this year, with further expansion continuing into 2027. The updates were highlighted as part of a broader set of milestones shared by the company at Aspen Ideas: Health.
Per management, glucose is relevant to everyone, and a better understanding of glucose patterns can help prevent serious health complications. The company is working to expand access to glucose biosensing to bring preventive, personalized care closer to reality and make the Stelo app experience more approachable with real-time insights that help people act earlier, before disease takes hold.
Likely Trend of DXCM Stock Following the News
Following the announcement, DXCM shares lost 0.2% at yesterday’s closing. Year to date, the stock has gained 3.8% against the industry’s 18.3% decline. The S&P 500 has risen 7.4% in the same timeframe.
The rollout of the redesigned Stelo app and the planned international expansion may strengthen DexCom’s position in the growing glucose monitoring and metabolic health market. By enhancing the user experience and extending access to new geographic markets, the company is broadening the appeal of its Stelo platform beyond traditional diabetes management. The developments could support long-term revenue growth while reinforcing DexCom’s leadership in glucose biosensing technology.
DXCM currently has a market capitalization of $26.65 billion.
Image Source: Zacks Investment Research
More on the News
The reimagined Stelo app has been developed to help users better understand how everyday factors such as food, physical activity, sleep and stress affect their glucose levels and overall well-being. The updated experience aims to simplify glucose data and provide insights that are easier to interpret and act upon, supporting the growing shift toward preventive and personalized healthcare.
In addition to the app rollout, DexCom highlighted the recent FDA clearance of the Stelo for pediatric use. The recent clearance expanded its indication from adults aged 18 and older not using insulin to include children aged 2 years and older who are not using insulin. The approval comes as youth-onset Type 2 diabetes and metabolic syndrome continue to rise in the United States, providing families with greater access to glucose insights and improving metabolic health awareness from an early age.
Industry Prospects Favoring the Market
Going by the data provided by Grandview Research, the continuous glucose monitoring (CGM) devices market was valued at $15.47 billion in 2026 and is expected to witness a CAGR of 15.1% through 2033.
Factors like the growing cases of diabetes, the increasing adoption of CGM devices, growing clinical needs, technological innovation and shifting care models are boosting the market’s growth.
Other News
At the recent Investor Day event, DexCom unveiled its next-generation CGM, the Dexcom G8 system, which is expected to be launched in late 2027 or early 2028. Features include step change improvement in glucose performance, a 50% smaller form factor than Dexcom G7 and advanced sensing capabilities.
Some better-ranked stocks from the broader medical space are BrightSpring Health (BTSG - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .
BrightSpring Health, currently sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2026 adjusted earnings per share (EPS) of 39 cents, which beat the Zacks Consensus Estimate by 34.5%. Revenues of $3.61 billion surpassed the Zacks Consensus Estimate by 8.35%. You can see the complete list of today’s Zacks #1 Rank stocks here.
BrightSpring Health has an estimated long-term earnings growth rate of 46.5%. BTSG’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 14.6%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
GMED has an estimated long-term earnings growth rate of 10.2%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has a long-term estimated growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
View the Zacks #1 Rank List
Image: Bigstock
DexCom to Roll Out Reimagined Stelo App With Global Expansion Plans
Key Takeaways
DexCom (DXCM - Free Report) recently announced that it will begin rolling out its fully reimagined Stelo app experience in the United States starting in July. The updated app, available for Apple iPhone and Android users, is designed to make glucose insights more accessible and actionable for individuals seeking to better understand their metabolic health.
Alongside the app launch, DexCom reiterated its plans to expand Stelo internationally. The platform is expected to launch in the United Kingdom, Australia, New Zealand and South Korea later this year, with further expansion continuing into 2027. The updates were highlighted as part of a broader set of milestones shared by the company at Aspen Ideas: Health.
Per management, glucose is relevant to everyone, and a better understanding of glucose patterns can help prevent serious health complications. The company is working to expand access to glucose biosensing to bring preventive, personalized care closer to reality and make the Stelo app experience more approachable with real-time insights that help people act earlier, before disease takes hold.
Likely Trend of DXCM Stock Following the News
Following the announcement, DXCM shares lost 0.2% at yesterday’s closing. Year to date, the stock has gained 3.8% against the industry’s 18.3% decline. The S&P 500 has risen 7.4% in the same timeframe.
The rollout of the redesigned Stelo app and the planned international expansion may strengthen DexCom’s position in the growing glucose monitoring and metabolic health market. By enhancing the user experience and extending access to new geographic markets, the company is broadening the appeal of its Stelo platform beyond traditional diabetes management. The developments could support long-term revenue growth while reinforcing DexCom’s leadership in glucose biosensing technology.
DXCM currently has a market capitalization of $26.65 billion.
Image Source: Zacks Investment Research
More on the News
The reimagined Stelo app has been developed to help users better understand how everyday factors such as food, physical activity, sleep and stress affect their glucose levels and overall well-being. The updated experience aims to simplify glucose data and provide insights that are easier to interpret and act upon, supporting the growing shift toward preventive and personalized healthcare.
In addition to the app rollout, DexCom highlighted the recent FDA clearance of the Stelo for pediatric use. The recent clearance expanded its indication from adults aged 18 and older not using insulin to include children aged 2 years and older who are not using insulin. The approval comes as youth-onset Type 2 diabetes and metabolic syndrome continue to rise in the United States, providing families with greater access to glucose insights and improving metabolic health awareness from an early age.
Industry Prospects Favoring the Market
Going by the data provided by Grandview Research, the continuous glucose monitoring (CGM) devices market was valued at $15.47 billion in 2026 and is expected to witness a CAGR of 15.1% through 2033.
Factors like the growing cases of diabetes, the increasing adoption of CGM devices, growing clinical needs, technological innovation and shifting care models are boosting the market’s growth.
Other News
At the recent Investor Day event, DexCom unveiled its next-generation CGM, the Dexcom G8 system, which is expected to be launched in late 2027 or early 2028. Features include step change improvement in glucose performance, a 50% smaller form factor than Dexcom G7 and advanced sensing capabilities.
DexCom, Inc. Price
DexCom, Inc. price | DexCom, Inc. Quote
DXCM’s Zacks Rank & Key Picks
DexCom currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are BrightSpring Health (BTSG - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .
BrightSpring Health, currently sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2026 adjusted earnings per share (EPS) of 39 cents, which beat the Zacks Consensus Estimate by 34.5%. Revenues of $3.61 billion surpassed the Zacks Consensus Estimate by 8.35%. You can see the complete list of today’s Zacks #1 Rank stocks here.
BrightSpring Health has an estimated long-term earnings growth rate of 46.5%. BTSG’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 14.6%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.
GMED has an estimated long-term earnings growth rate of 10.2%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%.
Intuitive Surgical has a long-term estimated growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.